Catalog No.
PAE16601
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Ramucirumab
Specificity
The product is specific for Ramucirumab. This antibody serves as an excellent positive control for Ramucirumab immunogenicity (ADA) assays.
Concentration
1.97 mg/ml
Purification
Antigen affinity purification.
Accession
CAS: 947687-13-0
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Rabbit polyclonal to LY3009806.
Background
Ramucirumab (LY3009806) is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.
Advances in Molecular Imaging of VEGFRs: Innovations in Imaging and Therapeutics., PMID:40508182
Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim., PMID:40468685
Therapeutic management of patients with advanced thymic malignancies: A review for clinicians., PMID:40334289
Toxicity Profile and Efficacy of Docetaxel Following Paclitaxel- or Pemetrexed-Platinum Chemotherapy Alone or in Combination With Immune Checkpoint Inhibitors in NSCLC Patients: A Single Institution Retrospective Analysis., PMID:40220012
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)., PMID:40155326
Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study., PMID:40152313
Comparison of the prognostic effect of taxane regimens combined with ramucirumab before nivolumab for advanced gastric cancer., PMID:40095335
Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial., PMID:40070819
Complete Remission with Nivolumab Monotherapy of Advanced Gastric Neuroendocrine Carcinoma., PMID:40024686
In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss., PMID:39979532
Monoclonal Antibodies and Small-Molecule Inhibitors Associated Osteonecrosis of Jaw: A Retrospective Pharmacovigilance Study., PMID:39922223
Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)., PMID:39905373
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial., PMID:39847172
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors., PMID:39834129
Development of treatment strategies for advanced HER2-positive gastric cancer: Insights from clinical trials., PMID:39805409
Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma., PMID:39769351
Circulating miR-23b-3p, miR-30e-3p, and miR-205-5p as Novel Predictive Biomarkers for Ramucirumab-Paclitaxel Therapy Outcomes in Advanced Gastric Cancer., PMID:39769259
Addressing the unmet need in NSCLC progression with advances in second-line therapeutics., PMID:39759220
[A Case of Pathological Complete Response after Nivolumab Therapy in Unresectable Advanced Gastric Cancer]., PMID:39721791
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab., PMID:39656165
Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma., PMID:39647858
Impact of ABCB1 single-nucleotide variants on early, extremely severe neutropenia induced by paclitaxel/nanoparticle albumin-bound paclitaxel in patients with gastric cancer., PMID:39622587
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC., PMID:39622410
Systemic Therapy for Hepatocellular Carcinoma., PMID:39608951
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial., PMID:39557058
Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study)., PMID:39507035
A critical analysis of design, binding pattern and SAR of benzo-fused heteronuclear compounds as VEGFR-2 inhibitors., PMID:39488171
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY)., PMID:39453771
Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab., PMID:39453578
Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment., PMID:39434017
RE: Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)., PMID:39412862
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)., PMID:39378386
Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study., PMID:39370483
Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study., PMID:39300169
Efficacy and safety of ramucirumab in gastric or gastroesophageal cancer: A systematic review and meta-analysis., PMID:39299442
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial., PMID:39250905
Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials., PMID:39160484
A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer., PMID:39120923
Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis., PMID:39102039
Ramucirumab in second‑line advanced colorectal cancer therapy: A study on therapeutic outcomes and hepatic sinusoidal platelet aggregation., PMID:39081965
Synthesis of chitosan polyethylene glycol antibody complex for delivery of Imatinib in lung cancer cell lines., PMID:39072816
BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report., PMID:39072179
Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease., PMID:39048364
Systemic Therapies for Hepatocellular Carcinoma in India., PMID:38975606
Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial., PMID:38925825
Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks Is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors., PMID:38866528
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)., PMID:38857846
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial., PMID:38851207
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)., PMID:38842657
Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study., PMID:38830895
For research use only. Not for human or drug use.
